144 related articles for article (PubMed ID: 33549195)
1. Hepatitis B reactivation after chemoimmunotherapy: screen before treatment.
Hwang JP; Ferrajoli A; Lok AS
Lancet; 2021 Feb; 397(10273):510. PubMed ID: 33549195
[No Abstract] [Full Text] [Related]
2. Hepatitis B surface antigen seroreversion in a T-cell lymphoma patient.
Chen HW; Lin SA; Lin HC; Kao WY
J BUON; 2011; 16(2):374-6. PubMed ID: 21766517
[No Abstract] [Full Text] [Related]
3. [Reactivation of hepatitis B virus in a patient treated for non-Hodgkin B diffuse large cell lymphoma with rituximab: about a case].
Houssou B; Massi RM; Camara M; Mifdal H; Nourichafi N; Zafad S; Oukkache B
Pan Afr Med J; 2015; 22():22. PubMed ID: 26664523
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
5. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with entecavir for reactivation of hepatitis B virus following systemic chemotherapy in a hepatitis B surface antigen-negative patient with colorectal cancer.
Okagawa Y; Takada K; Hisai H; Koshiba Y; Wada H; Miyazaki E; Kanari Y; Kawano Y; Iyama S; Hayashi T; Sato T; Sato Y; Miyanishi K; Kobune M; Takimoto R; Kato J
Intern Med; 2014; 53(16):1759-62. PubMed ID: 25130106
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
8. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.
Sanchez MJ; Buti M; Homs M; Palacios A; Rodriguez-Frias F; Esteban R
J Hepatol; 2009 Dec; 51(6):1091-6. PubMed ID: 19836097
[TBL] [Abstract][Full Text] [Related]
9. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
[No Abstract] [Full Text] [Related]
10. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma.
Muraishi J; Shibata M; Honma Y; Hiura M; Abe S; Harada M
Intern Med; 2017; 56(15):1967-1971. PubMed ID: 28768965
[TBL] [Abstract][Full Text] [Related]
11. Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen.
Dominguez N; Manzano ML; Muñoz R; Martin A; Fernandez I; Castellano G
Leuk Lymphoma; 2015 Apr; 56(4):1160-3. PubMed ID: 25115508
[No Abstract] [Full Text] [Related]
12. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
13. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature.
Türker K; Albayrak M; Öksüzoğlu B; Balc E; Oğan MC; Iskender G; Altuntaş F
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):39-45. PubMed ID: 25076063
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B reactivation and timing for prophylaxis.
Tuna N; Karabay O
World J Gastroenterol; 2015 Feb; 21(7):2263-4. PubMed ID: 25717269
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine.
Rago A; Ridola L; Lichtner M; Mecarocci S; Marocco R; Cenfra N; Belvisi V; Mastroianni CM; Cimino G
J Antimicrob Chemother; 2012 Feb; 67(2):510-1. PubMed ID: 22110085
[No Abstract] [Full Text] [Related]
16. [Impending liver failure after chemoimmunotherapy-induced reactivation of hepatitis B - successful treatment with entecavir].
Lock G; Helmich F; Bertram M
Dtsch Med Wochenschr; 2012 Jun; 137(23):1248-50. PubMed ID: 22644491
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
Molica S; Levato L; Mirabelli R; Tedeschi A; Lentini M
Leuk Lymphoma; 2018 Nov; 59(11):2734-2736. PubMed ID: 29465275
[No Abstract] [Full Text] [Related]
20. Surveillance and treatment protocols to detect and treat hepatitis B virus reactivation in hepatitis B surface antigen-negative/antibody to hepatitis B core antigen-positive patients receiving chemotherapy for onco-hematologic malignancies.
Marignani M; Marzano A
J Clin Oncol; 2011 Mar; 29(8):e210; author reply e211. PubMed ID: 21220585
[No Abstract] [Full Text] [Related]
[Next] [New Search]
